The Challenging Anticoagulant Therapy in Patient with COVID-19-Associated Coagulopathy
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.
WHO. Coronavirus disease situation report. World Health Organization. vol. 19. 2020.
Lippi G. D-dimer is associated with severity of Coronavirus disease 2019: A pooled D-dimer is associated with severity of Coronavirus disease 2019: A pooled analysis. 2020:2019–21. https://doi.org/10.1055/s-0040-1709650.
Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in Caucasian patients. Br J Haematol. 2020. https://doi.org/10.1111/bjh.16749.
Adhikari SP, Meng S, Wu Y, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. 2020:1–12.
Mezalek ZT, Khibri H, Ammouri W, et al. COVID-19 associated coagulopathy and thrombotic complications 2020. https://doi.org/10.1177/1076029620948137.
Ozma MA, Maroufi P, Khodadadi E. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period 2020;2.
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–98. https://doi.org/10.1007/s00134-020-06062-x.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020:1094–9. https://doi.org/10.1111/jth.14817.
McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2019:1–9. https://doi.org/10.1016/S2665-9913(20)30121-1.
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:4–8. https://doi.org/10.3389/fimmu.2020.01441.
Suresh M V, Balijepalli S, Zhang B, et al. Hypoxia-inducible factor (HIF)-1α promotes inflammation and injury following aspiration-induced lung injury in mice. Shock. 2019;52.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7. https://doi.org/10.1111/jth.14768.
Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020:1023–6. https://doi.org/10.1111/jth.14810.
Turpie AGG. Selective factor Xa inhibition with fondaparinux: From concept to clinical benefit. Eur Hear Journal. 2008;10 (Suppl):1–7. https://doi.org/10.1093/eurheartj/sun003.
Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am J Cardiovasc Drugs. 2005;5:121–30. https://doi.org/10.2165/00129784-200505020-00006.
Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–40. https://doi.org/10.1001/archinte.162.16.1833.
British Thoracic Society. BTS Guidance on Venous Thromboembolic Disease in patients with COVID-19. Br Thorac Soc. 2020;2:7.
Ramacciotti E, Macedo AS, Biagioni RB, et al. Evidence-based practical guidance for the antithrombotic management in patients with Coronavirus disease (COVID-19) in 2020. Clin Appl Thromb. 2020;26. https://doi.org/10.1177/1076029620936350.
AlHajri L, Gebran N. The use of low molecular weight heparin for venous thromboembolism prophylaxis in medical patients: How much are we adherent to the guidelines? Open J Intern Med. 2015;5:81–91. https://doi.org/10.4236/ojim.2015.54012.
Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets. 2020;31:674–9. https://doi.org/10.1080/09537104.2020.1760230.
Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series 2020:1–4. https://doi.org/10.1111/jth.14828.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.